Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Journal of the National Cancer Institute|January 8, 2019
Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint InhibitorsAlexandre Vivot, Perrine Créquit, Raphaël PorcherClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2018
Impact of Biomarker-based Design Strategies on the Risk of False-Positive Findings in Targeted Therapy EvaluationTat-Thang Vo, Alexandre Vivot, Raphaël PorcherJournal of Clinical Epidemiology|April 8, 2020
Bayesian analysis from phase III trials was underused and poorly reported: a systematic reviewDavid Ferreira, Alexandre Vivot, Pierre Diemunsch, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 19, 2014
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugsAlexandre Vivot, Isabelle Boutron, Philippe Ravaud, et al.Journal of Cancer Policy|July 2, 2022
Availability of results of academic randomized trials involving cooperative groups in oncology in France: A systematic search of clinical trial registriesPerrine Créquit, Alexandre Vivot, Jules Grégory, et al.Journal of Medical Internet Research|May 17, 2018
Mapping of Crowdsourcing in Health: Systematic ReviewPerrine Créquit, Ghizlène Mansouri, Mehdi Benchoufi, et al.Sleep Medicine|October 16, 2012
A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs SyndromeImad Ghorayeb, Antoine Bénard, Alexandre Vivot, et al.Journal of Clinical Epidemiology|December 16, 2018
Living network meta-analysis was feasible when considering the pace of evidence generationPerrine Créquit, Tania Martin-Montoya, Nassima Attiche, et al.American Journal of Preventive Medicine|November 23, 2019
A Methodologic Systematic Review of Mobile Health Behavior Change Randomized TrialsTheodora Oikonomidi, Alexandre Vivot, Viet-Thi Tran, et al.Scientific Reports|August 2, 2017
Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker TestingAlexandre Vivot, Isabelle Boutron, Geoffroy Béraud-Chaulet, et al.Pageof 3